SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalculus Vct Regulatory News (CLC)

Share Price Information for Calculus Vct (CLC)

Share Price is delayed by 15 minutes
Get Live Data
53.25    0.00 (0.00%)
Bid:
48.00
Ask:
58.50
Spread: 10.50 (21.875%)
Market Cap: £51.93m
CLC Live PriceLast checked at - London Stock Exchange

Intraday Calculus Vct Share Chart

Interim Management Statement

17 Jan 2011 14:58

Investec Structured Products Calculus VCT plc

Interim Management Statement

17 January 2011

Investec Structured Products Calculus VCT plc ("the Company") announces its Interim Management Statement for the period from 1 September 2010 to 30 November 2010. This Statement also includes relevant financial information between the end of the period to the date of this Statement.

The Company is a tax efficient listed company which aims to achieve a regular tax free dividend stream together with capital growth for private investors. The Company brings together Investec Structured Product's award winning expertise in structured products and Calculus Capital's award winning expertise in venture capital.

Investec Structured Products Calculus VCT plc was launched in March 2010, and has raised £4.79 million to date (before expenses).

Headlines

- The unaudited net asset value ("NAV") per Ordinary Share as at 30 November2010 was 97.98 pence (including current period revenue) compared to 94.55pence at 31 August 2010 and 95.00 pence immediately following the close of theinitial fundraising on 30 April 2010.

- The Company launched a top up offer of Ordinary Shares in September 2010, raising £0.92 million (before expenses) before closing in December 2010.

- The Company made a second qualifying venture capital investment during theperiod, investing £299,377 in Lime Technology, a leading provider of renewablebuilding materials to the construction industry.

Since 30 November 2010 the unaudited NAV (including current period revenue) has risen to 101.23 pence as at 31 December 2010.

Investment in Structured Products

As at 30 November 2010, the following investments had been made instructured products. The structured products will achieve their target returnsubject to the Final Index Level of the FTSE 100 being higher than the InitialIndex Level*. The capital is at risk on a one for one basis ("CAR") if theFTSE 100 Index falls more than 50% at any time during the investment term andfails to fully recover at maturity such that the Final Index Level is belowthe Initial Index Level. FTSE 100 Return/ % of Initial Capital Investable Index at Risk Application

Issuer Strike Date Level No. of Units Unit Purchase Price Maturity Date (CAR) Money The Royal Bank 05/05/2010 5342 275,000 £0.96

12/05/2015 162.5% if 6.40%of Scotland FTSE 100plc higher*; CAR if FTSE 100 falls by more than 50%Investec Bank 14/05/2010 5263 500,000 £0.9791 19/11/2015 185% if 11.87%plc FTSE 100 higher*; CAR if FTSE 100 falls by more than 50%Santander 25/05/2010 4941 350,000 £0.9898 18/11/2015 185% if 8.40%Global Banking FTSE 100and Markets higher*;(Abbey CAR ifNational FTSE 100Treasury falls byServices plc) more than 50%Nomura Bank 28/05/2010 5188 350,000 £0.98 20/02/2013 137% if 8.32%International FTSE 100plc higher*; CAR if FTSE 100 falls by more than 50%

Morgan Stanley 10/06/2010 5133 500,000 £1.00 17/12/2012 134% if 12.13% FTSE 100 higher*; CAR if FTSE 100 falls by more than 50%HSBC Bank plc 01/07/2010 4806 500,000 £1.00

06/07/2012 125.1% if 12.13% FTSE 100 higher*; CAR if FTSE 100 falls by more than 50%

\* The Final Index Level is calculated using `averaging', meaning that the average of the closing levels of the FTSE 100 is taken on each Business Day over the last 2 - 6 months of the structured product plan term (the length of the averaging period differs for each plan).

The use of averaging to calculate the return can reduce adverse effects of a falling market or sudden market falls shortly before maturity. Equally, it can reduce the benefits of an increasing market or sudden market rises shortly before maturity.

The total amount invested in structured products as at 30 November 2010 was £2,442,980, representing 59.25 per cent. of net funds raised.

Qualifying Venture Capital Investment

In November 2010, £299,377 was invested in Lime Technology Limited("Lime"). The investment comprised £49,377 in B shares and £250,000 in 7 percent. long term loan stock, the investment in B ordinary shares representing0.47 per cent. of the share capital of Lime. The total funding round in Limewas £2.58 million, with £1.28 million also being invested by Calculus CapitalEIS Funds.Lime, which was established in 2002, produces renewable low carbonbuilding materials for the construction industry. The company's lead product,Tradical® Hemcrete®, is a negative carbon bio-composite product comprised ofhemp and lime based binder. Through its subsidiary, Hemp Technology, Limecontrols the hemp supply chain from seed to finished wall.

The total amount invested in qualifying venture capital investments as at 30 November 2010 was £549,377 representing 13.32 per cent of net funds raised.

C Share OfferIn September 2010, shareholders approved resolutions enabling theCompany to establish and raise money for a separate fund through the issue ofC ordinary shares of 1 pence each in the capital of the Company ("C Shares").The C Share offer to raise £25 million was launched on 7 January 2011 ("CShare Offer").The C Shares fund will be managed separately from the OrdinaryShares fund, with an investment remit similar to that of the Ordinary Sharesfund, but will include the ability to invest in structured products linked tothe performance of certain global equity indices in addition to the FTSE 100.The target return profile for the C Shares fund will be an annualtarget dividend of 4.5 pence per C Share for the first five years, an interimreturn of 47.5 pence per C Share by 14 March 2017 (which would (including thepayment of annual dividends) return the net 70.0 pence investment) with afurther 45.0 pence per C Share being returned by 14 March 2019 (which wouldachieve a total return of 115 pence per C Share by this date).The C Share Offer will close on 5 April 2011 for the 2010/2011 taxyear and on 30 April 2011 for the 2011/2012 tax year (unless extended),allowing investors to subscribe for C Shares in both the 2010/2011 and2011/2012 tax years. The offer price per C Share is £1.00. The C Share Offeris conditional on receiving applications for, in aggregate, a minimum of £1million. If less than £1 million is applied for by the closing date (as may beextended), the Offer will lapse.

Other than as discussed above, the Board is not aware of any significant events or transactions which have occurred in the period from incorporation and the date of this Statement and which have a material impact on the financial position of the Company.

For further information, please contact:

Gary Dale (Investec Structured Products) 020 7597 4065

John Glencross (Calculus Capital Limited) 020 7493 4940

vendor
Date   Source Headline
8th Sep 20201:01 pmRNSPublication of a Prospectus
8th Sep 202012:51 pmRNSPublication of a Prospectus
3rd Sep 20202:46 pmRNSIssue of Equity
31st Jul 202012:46 pmRNSDirector/ PDMR shareholding
3rd Jul 20204:42 pmRNSResult of AGM
3rd Jul 20204:09 pmRNSDirectorate Change
18th Jun 20204:45 pmRNSTransaction in Own Shares
17th Jun 20205:34 pmRNSNet Asset Value 31 May 2020
17th Jun 20205:07 pmRNSNet Asset Value 31 May 2020
27th May 20203:40 pmRNSAnnual Financial Report
21st May 20204:09 pmRNSDirector Declaration
3rd Apr 20204:15 pmRNSIssue of Equity
31st Mar 20202:18 pmRNSNet Asset Value(s) and Impact of Covid-19
19th Dec 20194:22 pmRNSNet Asset Value(s)
12th Dec 201911:29 amRNSIssue of Equity and Correction
18th Oct 20194:40 pmRNSHalf-year Report
24th Sep 20192:18 pmRNSPublication of a Prospectus
6th Sep 201911:22 amRNSIssue of Equity
4th Sep 20193:20 pmRNSNet Asset Value(s)
31st Jul 20192:48 pmRNSTransaction in Own Shares
4th Jul 20194:24 pmRNSResult of AGM
26th Jun 20192:25 pmRNSIssue of Equity
14th Jun 20199:52 amRNSNet Asset Value(s)
9th May 20195:49 pmRNSAnnual Financial Report - Replacement
9th May 20194:12 pmRNSAnnual Financial Report
5th Apr 20193:49 pmRNSIssue of Equity
28th Feb 201910:41 amRNSIssue of Equity
22nd Feb 20194:46 pmRNSNet Asset Value(s)
4th Feb 201910:02 amRNSDirectorate Change
24th Jan 201910:19 amRNSHolding(s) in Company
23rd Jan 201912:46 pmRNSIssue of Equity
16th Jan 20192:45 pmRNSNet Asset Value(s)
8th Jan 20193:49 pmRNSNet Asset Value(s)
18th Dec 201812:42 pmRNSDirector Declaration
13th Dec 20183:34 pmRNSDirectorate Change
6th Nov 201810:17 amRNSTransaction in Own Shares
23rd Oct 20184:32 pmRNSHalf-year Report
9th Oct 20183:21 pmRNSGM Statement
17th Sep 20184:33 pmRNSHolding(s) in Company
17th Sep 20184:33 pmRNSHolding(s) in Company
14th Sep 20187:00 amRNSPublication of a Prospectus
22nd Aug 20189:24 amRNSDirector Declaration
21st Aug 20184:54 pmRNSTransaction in Own Shares
16th Aug 20183:32 pmRNSNet Asset Value(s)
2nd Aug 20181:31 pmRNSIssue of Equity
19th Jul 20184:32 pmRNSNet Asset Value(s)
3rd Jul 201812:21 pmRNSResult of Meeting & Offer for subscription
19th Jun 20183:38 pmRNSNet Asset Value(s)
22nd May 20184:52 pmRNSDividend Declaration
17th May 20183:48 pmRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.